SG Americas Securities LLC Takes $824,000 Position in Novavax, Inc. (NASDAQ:NVAX)

SG Americas Securities LLC bought a new stake in Novavax, Inc. (NASDAQ:NVAXFree Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 171,618 shares of the biopharmaceutical company’s stock, valued at approximately $824,000. SG Americas Securities LLC owned approximately 0.14% of Novavax as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Geneos Wealth Management Inc. boosted its stake in shares of Novavax by 124.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 1,809 shares of the biopharmaceutical company’s stock valued at $133,000 after purchasing an additional 1,004 shares in the last quarter. US Bancorp DE boosted its stake in shares of Novavax by 41.8% in the 1st quarter. US Bancorp DE now owns 2,083 shares of the biopharmaceutical company’s stock valued at $154,000 after purchasing an additional 614 shares in the last quarter. Neuberger Berman Group LLC boosted its stake in shares of Novavax by 34.9% in the 1st quarter. Neuberger Berman Group LLC now owns 2,764 shares of the biopharmaceutical company’s stock valued at $204,000 after purchasing an additional 715 shares in the last quarter. Toroso Investments LLC boosted its stake in shares of Novavax by 15.3% in the 1st quarter. Toroso Investments LLC now owns 3,297 shares of the biopharmaceutical company’s stock valued at $243,000 after purchasing an additional 437 shares in the last quarter. Finally, PDT Partners LLC acquired a new stake in shares of Novavax in the 1st quarter valued at $243,000. Institutional investors and hedge funds own 53.04% of the company’s stock.

Novavax Stock Down 2.7 %

Shares of NASDAQ NVAX opened at $4.65 on Tuesday. The firm’s 50-day simple moving average is $4.63 and its 200 day simple moving average is $5.51. The company has a market cap of $650.77 million, a price-to-earnings ratio of -0.84 and a beta of 1.59. Novavax, Inc. has a 12-month low of $3.53 and a 12-month high of $11.36.

Novavax (NASDAQ:NVAXGet Free Report) last released its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.95). The business had revenue of $291.34 million for the quarter, compared to the consensus estimate of $310.96 million. During the same quarter in the previous year, the firm posted ($2.28) EPS. The company’s revenue for the quarter was down 18.5% on a year-over-year basis. On average, equities analysts expect that Novavax, Inc. will post -0.88 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages recently issued reports on NVAX. HC Wainwright reduced their price target on shares of Novavax from $35.00 to $19.00 and set a “buy” rating on the stock in a research report on Friday, March 1st. StockNews.com upgraded shares of Novavax from a “sell” rating to a “hold” rating in a research report on Friday, December 8th.

Get Our Latest Report on Novavax

About Novavax

(Free Report)

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.

Read More

Want to see what other hedge funds are holding NVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novavax, Inc. (NASDAQ:NVAXFree Report).

Institutional Ownership by Quarter for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.